Atara gets FDA approval to start two phase 3 studies to assess tabelecleucel in patients with EBV+PTLD
The Company plans to initiate these studies imminently. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.